Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits

Journal of Controlled Release

Volumn 94, Issue 1, 2004, Pages 187-193

  Lukyanov, Anatoly N ^a   Hartner, William C ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Enhanced permeability and retention effect; Gamma imaging; Infarct targeting; PEG lipid conjugates; Polymeric micelles

Indexed keywords

AMINES; BLOOD; BLOOD VESSELS; DIAGNOSIS; DRUG PRODUCTS; MICELLES; MUSCLE; POLYETHYLENE GLYCOLS;

DRUG CARRIERS; ENHANCED PERMEABILITY AND RETENTION (EPR);

DRUG DOSAGE;

DIAGNOSTIC AGENT; DRUG CARRIER; MACROGOL; PHOSPHATIDYLETHANOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; HEART INFARCTION; HEART MUSCLE; MICELLE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RABBIT; ZETA POTENTIAL;

EID: 0347996095     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2003.10.008     Document Type: Article

References (37)

1. Kwon G.S., Kataoka K. Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 16:1995;295-309.
2. Jones M., Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48:1999;101-111.
3. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release. 73:2001;137-172.
4. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release. 82:2002;189-212.
5. Trubetskoy V.S., Torchilin V.P. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv. Drug Deliv. Rev. 16:1995;311-320.
6. Weissig V., Whiteman K.R., Torchilin V.P. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm. Res. 15:1998;1552-1556.
7. Lukyanov A.N., Gao Z., Mazzola L., Torchilin V.P. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm. Res. 19:2002;1424-1429.
8. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46:2001;169-185.
9. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:1986;6387-6392.
10. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55:1995;3752-3756.
11. Gabizon A.A. Liposome circulation time and tumor targeting: implications for cancer therapy. Adv. Drug Deliv. Rev. 16:1995;285-294.
12. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6039-6044.
13. Caride V.J., Zaret B.L. Liposome accumulation in regions of experimental myocardial infarction. Science. 198:1977;735-738.
14. Mueller T.M., Marcus M.L., Mayer H.E., Williams J.K., Hermsmeyer K. Liposome concentration in canine ischemic myocardium and depolarized myocardial cells. Circ. Res. 49:1981;405-415.
15. Caride V.J., Twickler J., Zaret B.L. Liposome kinetics in infarcted canine myocardium. J. Cardiovasc. Pharmacol. 6:1984;996-1005.
16. Palmer T.N., Caride V.J., Caldecourt M.A., Twickler J., Abdullah V. The mechanism of liposome accumulation in infarction. Biochim. Biophys. Acta. 797:1984;363-368.
17. Torchilin V.P., Narula J., Halpern E., Khaw B.A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta. 1279:1996;75-83.
18. Khaw B.A., Beller G.A., Haber E., Smith T.W. Localization of cardiac myosin-specific antibody in myocardial infarction. J. Clin. Invest. 58:1976;439-446.
19. Grant C.W., Karlik S., Florio E. A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn. Reson. Med. 11:1989;236-243.
20. Torchilin V.P. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsulation. 15:1998;1-19.
21. Torchilin V.P. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 54:2002;235-252.
22. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release. 74:2001;47-61.
23. Maxwell M.P., Hearse D.J., Yellon D.M. Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc. Res. 21:1987;737-746.
24. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4607-4612.
25. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 83:1998;307-314.
26. Monsky W.L., Fukumura D., Gohongi T., Ancukiewcz M., Weich H.A., Torchilin V.P., Yuan F., Jain R.K. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59:1999;4129-4135.
27. Harrington K.J., Rowlinson-Busza G., Syrigos K.N., Vile R.G., Uster P.S., Peters A.M., Stewart J.S. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin. Cancer Res. 6:2000;4939-4949.
28. Harrington K.J., Mohammadtaghi S., Uster P.S., Glass D., Peters A.M., Vile R.G., Stewart J.S. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7:2001;243-254.
29. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 9:1990;253-266.
30. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271:1994;58-65.
31. Hansen J.F. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am. Heart J. 117:1989;290-295.
32. Sabri M.N., DiSciascio G., Cowley M.J., Alpert D., Vetrovec G.W. Coronary collateral recruitment: functional significance and relation to rate of vessel closure. Am. Heart J. 121:1991;876-880.
33. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 65:2000;271-284.
34. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
35. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
36. Banai S., Shweiki D., Pinson A., Chandra M., Lazarovici G., Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc. Res. 28:1994;1176-1179.
37. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.